Brandi R. Walker
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Brandi R. Walker has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Adam S. Kittai
Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
20 shared publications - Alexander He
The Ohio State University 1 Division of Hematology, Department of Internal Medicine Columbus, Ohio
20 shared publications - Alexander R. Marr
Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS 66160, USA
20 shared publications - Andrew D. Mitchell
Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio
20 shared publications - Arnau Peris-Cuesta
Division of Hematopoietic Biology and Malignancy, MD Anderson Cancer Center, Houston, Texas
20 shared publications - Britten K. Gordon
The Ohio State University 1 Division of Hematology, Department of Internal Medicine Columbus, Ohio
20 shared publications
Latest Publications
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
Effect of MS-553 on healthy immune cells.
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
Effect of MS-553 on healthy immune cells.
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S12 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
BTK mutant knock-in cell lines.
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S12 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
BTK mutant knock-in cell lines.
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
PKCβ is accessible and upregulated in dual-refractory CLL.
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
PKCβ is accessible and upregulated in dual-refractory CLL.
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
Effect of MS-553 on BCR Signaling.
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
Effect of MS-553 on BCR Signaling.
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
Effect of MS-553 on PKCβ and PKCε in CLL.
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
Effect of MS-553 on PKCβ and PKCε in CLL.
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
Effect of MS-553 on Wnt/β-catenin signaling.
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
Effect of MS-553 on Wnt/β-catenin signaling.
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
Clinical characteristics of BTKi resistant CLL patient samples
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
Clinical characteristics of BTKi resistant CLL patient samples
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
Effect of MS-553 towards co-culture systems.
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
Effect of MS-553 towards co-culture systems.
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
Supplementary Table S2 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
Supplementary Table S2 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
Characteristics of CLL patients with dual-refractory disease
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
Characteristics of CLL patients with dual-refractory disease